3.06% Oct 24, 05:02 PM
$2.76 Paid Annual
53.4% EPS $5.17
No Payout Increase Last Year
No Ex-Dividend Dates
Have Been Scheduled

NVS - Upcoming Dividend Payouts
Next Ex-Dividend Date None

Amount Declare Date Ex-Dividend Date ▲ Record Date Pay Date Payout Type
No Upcoming Dividend Dates
NVS has not yet officially announced its next dividend payout.

NVS - Dividend Yield & Stock Price History
Current Dividend Yield 3.06%

Arrow-right
5y
All

NVS - Dividend Payout History
Current Annual Payout $2.76

5y
All
Dividend payouts are split-adjusted

NVS - Dividend Growth History

Annualized Growth
1994-2012
Annualized Growth
1994-2004
Annualized Growth
2004-2008
Annualized Growth
2008-2012
Annualized Growth
Last 5 Yrs
Annualized Growth
Last 3 Yrs
Annual
Growth
2012
Consecutive
Years of
Increases
Reveal Dividend Growth History for NVS. 7.6% -2.2% No Payout Increase Last Year
Annual dividend amounts based on Ex-dividend date

NVS - Historical Annual Dividend Data & Growth
Payouts Increasing For No Payout Increase Last Year

Payout Amount Calendar Year Annual Growth
$2.4265 2013 -2.2%
$2.4822 2012 5.5%

NVS - Historical Dividend Data
Payouts Increasing For No Payout Increase Last Year

Payout Amount Declared Date Ex-Dividend Date Record Date Pay Date ▼ Qualified Dividend? Payout Type Frequency
$2.7598 2014-02-27 2014-03-03 2014-04-10 Unknown Regular Annual
$2.4265 2013-02-26 2013-02-28 2013-04-05 Unknown Regular Annual
$2.4822 2012-02-27 2012-02-29 2012-04-05 Unknown Regular Annual
$2.3527 2011-02-24 2011-02-28 2011-04-08 Unknown Regular Annual
$1.9484 2010-03-02 2010-03-04 2010-04-13 Unknown Regular Annual

Novartis (NVS) - News

  • Here at Dividend.com, we constantly emphasize the importance of strong fundamentals when it comes to making any investment decision. However, with...
  • If you're struggling to find attractive investment opportunities at home without taking on handfuls of risk, you're not alone. Many investors have...
  • Before Wednesday’s opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst...
  • Before Thursday's opening bell, a number of big name, dividend paying companies announced their quarterly earnings. Below, we look at these...
  • Novartis AG (ADR) Sells Diagnostics Business for $1.68B (NVS)

    On Monday, healthcare company Novartis AG (ADR) (NVS) announced that it has sold its diagnostics business for $1.68 billion in cash. NVS's Strategic Review As part of the company's strategic review, NVS has sold its blood transfusion diagnostics business to Barcelona-based Grifols. The business was previously a part of Chiron, a biotechnology company that was acquired by NVS in 2006. NVS's chief executive Joseph Jimenez reported that the sale was part of a company plan to focus on its larger businesses. The company's diagnostics business also works with Johnson & Johnson (JNJ) and with Hologic (HOLX). The deal has been approved by both of these companies. Additional Sales May be in NVS's Future NVS's decision to sell off the business was highly expected by analysts. The company may also decide to divest in its vaccines and diagnostics, over-the-counter (OTC) products, and animal health businesses. Several other pharmaceutical companies have been restructuring their businesses to meet investor demands. Stock Performance Novartis shares were mostly flat during pre-market trading Monday. The stock is up 22% YTD.

    The Bottom Line

    Shares of Novartis AG (ADR) (NVS) have a 3.28% yield based on Friday's closing price of $77.25. Novartis AG (ADR) (NVS) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • Jefferies reported on Thursday that healthcare company, Novartis AG (NVS) is now the top pick for European pharmaceuticals. The firm, which...
  • Supreme Court Of India Rejects Patent Protection for Novartis' Glivec (NVS)

    Healthcare solution provider, Novartis AG (NVS) failed to win patent protection for Glivec on Monday. The court in India has rejected patent protection for NVS's cancer drug Glivec. The denial of the patent protection came as a major disappointment to the company, but as a victory for makers of low priced generic drugs. India's generic drug industry has turned into a $13 billion a year industry, which comes to a great relief to a majority of the country's 1.2 billion residents who are unable to afford expensive patent protected drugs. India's Cipla Ltd and Natco Pharma Ltd are two companies that will benefit from the rejection of patent protection. The companies already sell a generic version of the drug at a price one-tenth of the patented drug. The decision to block the patent protection for NVS comes after a legal battle which began in 2006. There has been much controversy regarding high priced drugs in the country. Novartis shares were up 59 cents, or 0.83% during premarket trading Tuesday. The stock has increased 28% in the past year. The Bottom Line Shares of Novartis AG (NVS) have a 3.56% yield, based on Monday's closing price of $71.06. Novartis AG (NVS) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • JPMorgan Upgrades Novartis to "Overweight" (NVS)

    JPMorgan reported on Friday that it has upgraded healthcare product giant, Novartis AG (NVS) . The firm has increased its rating for the company from "Neutral" to "Overweight." An analyst from the firm commented, "we upgrade Novartis to overweight from Neutral with a new 18 month price target of Sfr 78 assuming the stock can approach a sector multiple by mid 2014 which reflects FCF growth beyond 2019 of just below 1%." Novartis shares were up 56 cents, or 0.81% during Friday morning trading. The stock has increased 28% in the past year. The Bottom Line Shares of Novartis AG (NVS) have a 3.64% yield, based on Friday morning's price of $69.57. Novartis AG (NVS) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • Novartis Reports Higher Profits; Chairman Steps Down (NVS)

    Healthcare solution provider, Novartis(NVS) reported a surge in earnings for the fourth quarter on Wednesday, beating analysts estimates. The Basel, Switzerland based company saw a 42% increase in fourth quarter profit, reporting earnings of $2.08 billion, or 84 cents per share, from $1.21 billion, or 49 cents per share last year. Excluding special items, earnings for the quarter came in at $3.10 billion, or $1.27 per share, beating analysts estimate of $1.19 per share. Revenue remained flat at $14.83 billion, from $14.78 billion last year. Sales during 2013 are expected to drop due to an expired patent on the company's hypertension drug Diovan. FY2012 profit increased by 4% to $9.62 billion from $9.25 billion last year. Additionally, the company announced that chief executive and chairman, Daniel Vasella will be leaving the board in February at the annual shareholders meeting. The board suggests that chairman of Bayer HealthCare, Joerg Reinhardt replace Vasella. Vasella has been with the company for a total of 25 years, spending 14 years as CEO, and 14 years as chairman. Novartis shares were up $2.72, or 4.18% during premarket trading Wednesday. The stock has increased 18% in the past year. The Bottom Line Shares of Novartis (NVS) have a 3.78% dividend yield, based on last night's closing stock price of $65.13. The stock has technical support in the $60-$62 price area. The shares are trading at all-time highs. Novartis(NVS) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • Deutsche Bank Downgrades Novartis to "Hold" (NVS)

    On Wednesday analysts at Deutsche Bank downgraded pharmaceutical company Novartis (NVS) as it does not see the company keeping up with its past outperformance of consensus expectations. The analysts downgraded NVS from "Buy" to "Hold." An analysts at Deutsche Bank commented, "Previously we were buyers of Novartis as its industry leading innovation had the potential to beat low consensus expectations. Despite some set-backs, the pipeline generally has delivered, and we expect this to continue going forward. Together with the shares' recent good performance, our concern is that consensus not only factors in pipeline success but now overshoots our long-term earnings forecasts. As such, we downgrade to Hold from Buy, expecting modest share price upside in 2013." Novartis shares were up 30 cents, or +0.46%, in premarket trading on Wednesday. The Bottom Line Shares of Novartis (NVS) have a 3.89% dividend yield, based on last night's closing stock price of $63.20. The stock has technical support in the $58-$60 price area. The shares are trading near its all-time highs. Novartis (NVS) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

Top-5-pitch